Search

Your search keyword '"Giobbie‐Hurder, Anita"' showing total 39 results

Search Constraints

Start Over You searched for: Author "Giobbie‐Hurder, Anita" Remove constraint Author: "Giobbie‐Hurder, Anita" Publisher american society of clinical oncology (asco) Remove constraint Publisher: american society of clinical oncology (asco)
39 results on '"Giobbie‐Hurder, Anita"'

Search Results

1. Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

2. Phase 2 trial of bavituximab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma.

4. Acupuncture for hot flashes in hormone receptor-positive breast cancer, a pooled analysis of individual patient data from parallel randomized trials.

5. Advanced imaging to assess longitudinal vascular changes in brain metastases treated with checkpoint inhibition.

6. Characterizing the tumor and immune landscape of melanoma patients treated with combined checkpoint blockade and MAPK targeted therapy.

7. Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis

9. CTEP 9557: A dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF mutant solid tumors.

10. Advanced imaging to assess longitudinal vascular changes in brain metastases treated with immune checkpoint inhibition.

11. Association of vitamin D intake with decreased risk of immune checkpoint inhibitor-induced colitis.

12. Phase Ib study to test the safety and activity of pembrolizumab (anti-PD-1) and trebananib (angiopoietin-2 inhibitor [Ang-2]) in patients with advanced solid tumors: Updated analysis of the colorectal cancer (CRC) cohort.

14. Analysis of colorectal cancer patients treated on ETCTN 10021: A multicenter randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation.

15. MYD88 L265P mutation and CDKN2A loss as early mutational events in primary central nervous system lymphomas.

16. Effect of dexamethasone in glioblastoma (GBM) patients on systemic and intratumoral T-cell responses induced by personalized neoantigen-targeting vaccine.

17. Phase II study of pembrolizumab in leptomeningeal carcinomatosis.

18. Mismatch repair deficiency in cholangiocarcinoma.

21. Association of distinct baseline tissue biomarkers with response to nivolumab (NIVO) and ipilimumab (IPI) in melanoma: CheckMate 064.

23. Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study

24. Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence

26. Impact of a pre-operative exercise intervention on Ki-67 and metabolic markers in women with early breast cancer.

27. Differences between gene mutation profile and outcome of Merkel cell polyomavirus (MCPyV) positive and negative Merkel cell carcinoma (MCC).

30. Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial

32. A phase II study of combined therapy with vemurafenib (vem) and high-dose interleukin-2 (aldesleukin; HD IL-2) in patients with metastatic melanoma.

34. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

36. Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib.

38. Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study

39. Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

Catalog

Books, media, physical & digital resources